Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Clinical Decisions in Connective Tissue Disease
share announcement

Clinical Decisions in Connective Tissue Disease

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Evidence Based Medicine".

Deadline for manuscript submissions: closed (10 March 2024) | Viewed by 3239

Special Issue Editor

Dr. Antonio-Javier Chamorro

E-Mail Website
Guest Editor
Faculty of Medicine, Adjunct of Internal Medicine, University Hospital of Salamanca (SACYL), 37007 Salamanca, Spain
Interests: Wernicke's encephalopathy; alcoholism; meta-analysis systemic review; connective tissue diseases

Special Issue Information

Dear Colleagues, 

Connective tissue diseases are a field in which most of the evidence described, regarding diagnosis and treatment, is scant and based mainly on very few randomized studies, case series, or, for the rarest diseases, isolated clinical cases. For all of these reasons, before beginning clinical trials or studies with a higher degree of evidence, it is necessary to know the state of knowledge through systematic reviews or meta-analyses. For this reason, I consider the possibility that this type of work can contribute to the scientific community to be very high, and more so in specific fields that are so infrequent within connective tissue diseases such as autoinflammatory syndromes, some types of immune-mediated inflammatory myopathies, or even responses to certain drugs in rare diseases. All of this is to give some examples. For all of the aforementioned reasons, we invite authors to send their articles related to these topics.

Dr. Antonio-Javier Chamorro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • systematic review
  • meta-analysis
  • connective tissue diseases
  • autoimmune diseases
  • immune system diseases

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

10 pages, 618 KiB  
Systematic Review
Plasma Exchange in Anti-Signal Recognition Particle Myopathy: A Systematic Review and Combined Analysis of Patient Individual Data
by Pablo Martínez-Rodríguez, María Escribano-Iglesias, Ángel-P. Crisolino-Pozas, Noelia Cubino-Boveda, Miriam López-Parra, Miguel Marcos and Antonio-J. Chamorro
J. Pers. Med. 2024, 14(5), 461; https://doi.org/10.3390/jpm14050461 - 27 Apr 2024
Viewed by 317
Abstract
Anti-signal recognition particle myopathy (anti-SRP myopathy) is a rare subtype of immune-mediated inflammatory myopathy characterized by muscle weakness and anti-SRP autoantibodies. Although plasma exchange (PE) is used in severe cases, its role remains unclear. A systematic review was conducted following PRISMA guidelines, identifying [...] Read more.
Anti-signal recognition particle myopathy (anti-SRP myopathy) is a rare subtype of immune-mediated inflammatory myopathy characterized by muscle weakness and anti-SRP autoantibodies. Although plasma exchange (PE) is used in severe cases, its role remains unclear. A systematic review was conducted following PRISMA guidelines, identifying 23 patients with anti-SRP myopathy treated with PE. Data on demographics, clinical features, laboratory findings, treatments, and outcomes were analyzed combining individual patient data if available. Sixteen (69.6%) patients were male, with muscle weakness as the predominant symptom in 100% of cases. After PE, most patients showed improvement in symptoms, and the proportion of patients with muscle weakness was reduced (p = 0.001). Relapse occurred in 17.4% of the cases. The incidence of adverse events was low (8.7%). Despite limitations, including a small sample size and heterogeneous data, our systematic review suggests that PE may be effective in inducing remission and controlling symptoms in anti-SRP myopathy, particularly in severe cases. Since evidence on PE in anti-SRP myopathy is limited, further research, including prospective multicenter studies, is warranted to understand better its efficacy and safety and establish its role in treatment algorithms. Full article
(This article belongs to the Special Issue Clinical Decisions in Connective Tissue Disease)
►▼ Show Figures

Figure 1

8 pages, 1980 KiB  
Case Report
Successful Treatment of SAPHO Syndrome Complicated with Ankylosing Spondylitis by Secukinumab: A Case Report
by Wei Tu, Daan Nie, Yuxue Chen, Cheng Wen and Zhipeng Zeng
J. Pers. Med. 2023, 13(3), 516; https://doi.org/10.3390/jpm13030516 - 13 Mar 2023
Cited by 2 | Viewed by 2584
Abstract
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is characterized by a wide range of dermatological and musculoskeletal manifestations, and its outcome has recently been improved greatly by optimizing management. However, the treatment strategies are not standardized and require further refinement. Secukinumab, a [...] Read more.
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is characterized by a wide range of dermatological and musculoskeletal manifestations, and its outcome has recently been improved greatly by optimizing management. However, the treatment strategies are not standardized and require further refinement. Secukinumab, a fully human monoclonal antibody targeting IL-17A, is approved for the treatment of autoimmune psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Here, a 53-year-old man was diagnosed with AS, and he presented scattered pustulosis in both hands and feet with a 5-year history of recurrent lumbosacral area pain and abnormal pain in the neck and front chest area. Secukinumab improved the patient’s cutaneous lesion and prevented musculoskeletal pain by substituting adalimumab. Although only a few cases have been reported that secukinumab can effectively treat SAPHO syndrome complicated with AS, the efficacy remains controversial. Therefore, we hope to provide a novel valuable therapeutic strategy for SAPHO syndrome management, particularly in patients with skin lesions. Full article
(This article belongs to the Special Issue Clinical Decisions in Connective Tissue Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop